Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, ... New ... Resources, Inc., one,of the world,s leading research and advisory firms for ... with biologic sales of more than $14 billion in 2006, and ...
... States Boyden Global Executive Search ,Helps Businesses Find the ... ... Boyden Global Executive Search of,Summit is featured in the September ... of the New Jersey Business and,Industry Association (NJBIA), the largest state ...
... N.C., Sept. 5 A study in ... the use of the GlycoMark,1,5-anhydroglucitol (1,5-AG) blood ... especially to target postprandial hyperglycemia (elevated,after-meal glucose ... achieving optimal glycemic control and reducing the ...
Cached Biology Technology:Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers 2Boyden's Summit Practice Featured in the September Issue of New Jersey Business Magazine 2Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes 2
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... the growing mobile commerce market, announces it has retained famous ... the 2015 International CES debut of the Wocket™ biometric smart ... at the NXT-ID booth January 6th and 7 th , ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... Biophysical Society is pleased to announce that it will ... with the International Biophysics Congress in Long Beach, California, ... talks and poster sessions that take place during the ... to discuss current policy issues facing our nation. The ...
... New research at the University of Chicago finds evidence ... the pain of loneliness: They create people in their ... not a very efficient way to alleviate ones loneliness, ... to do so, said Nicholas Epley, Assistant Professor of ...
... This release is also available in French . ... to community involvement today with a $1-million donation to ... and Hospital (MNI), affiliated with McGill University and the ... $40-million initiative to invest in people and expand facilities ...
Cached Biology News:Biophysical Society to host discussions on the teaching of evolution and on the energy crisis 2People not always needed to alleviate loneliness 2People not always needed to alleviate loneliness 3Building the future -- 21st century nano tools to repair the nervous system 2
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
... these culture chambers produce cell yields in ... range and are useful alternatives to multiple ... mechanical • strength and structural integrity • ... Certified nonpyrogenic and sterilized by gamma irradiation, ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
...
Biology Products: